Tag: ESOC
Acticor Biotech will present the clinical results of its phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024 – 04/15/2024 at 6:00 p.m.
To receive all Acticor Biotech financial information in real time, request it by email to [email protected] • Results of the phase 2/3 ACTISAVE clinical study in the treatment of stroke…
Participation of Acticor Biotech in ESOC 2023, the first European forum for stroke research – 05/26/2023 at 18:00
Paris, France, May 26, 2023 – 6:00 p.m. CEST – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies,…
Presentation of the positive results of the ACTIMIS phase 1b/2a study in the treatment of stroke at ESOC 2022 – 05/09/2022 at 18:15
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected] ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specializing in…